

## Paliperidone

### Introduction

Second generation antipsychotics (sometimes referred to as 'atypical' antipsychotics) are a newer class of antipsychotic medication than first generation 'typical' antipsychotics. Second generation antipsychotics are effective for the positive symptoms of schizophrenia. It is sometimes claimed that they are more effective than first generation antipsychotics in treating the negative symptoms of schizophrenia, although the evidence for this is weak. Negative symptoms include a lack of ordinary mental activities such as emotional expression, social engagement, thinking and motivation, whereas positive symptoms include the experiences of perceptual abnormalities (hallucinations) and fixed, false, irrational beliefs (delusions).

Second generation antipsychotics may also cause less extra-pyramidal side effects. These include dyskinesias such as repetitive, involuntary, and purposeless body or facial movements, Parkinsonism (cogwheel muscle rigidity, pill-rolling tremor and reduced or slowed movements), akathisia (motor restlessness, especially in the legs, and resembling agitation) and dystonias such as muscle contractions causing unusual twisting of parts of the body, most often in the neck. These effects are caused by the dopamine receptor antagonist action of these drugs. One explanation for differences in producing these side effects is that high potency first generation antipsychotics are usually selective dopamine receptor antagonists with a high affinity for the dopamine receptor and they induce extrapyramidal effects by the blockade of these dopamine receptors. In contrast, second generation antipsychotics generally have a lower affinity for the dopamine receptor and also block serotonin receptors, both of which mechanisms may play a role in mitigating the effects of dopamine blockade. Amisulpride is an exception to other second generation antipsychotics in that it is a pure dopamine receptor antagonist, however it tends to block

dopamine receptors more selectively in the limbic system relative to the nigrostriatal system, which is the site responsible for inducing extrapyramidal symptoms. In addition to amisulpride, olanzapine and quetiapine also tend to selectively block dopamine receptors in the mesolimbic system but target serotonin receptors.

This table summarises overall group effectiveness of paliperidone from information gained from randomised controlled trials (RCTs), however individual treatment programs need to be tailored by trained clinicians as response - both in symptoms and adverse effects - can vary between individuals.

### Method

Owing to the vast number of reviews on antipsychotics, we have included only information reported in the abstracts of Cochrane systematic reviews<sup>1</sup>. This is because the Cochrane internal review process ensures a high level of scientific rigor and meta-analyses are usually conducted, giving treatment effect sizes. Data from the abstracts were supplemented from the full text when clarification was required. We have included only Cochrane reviews that have been published from the year 2000 to date to ensure the latest available evidence is presented. When multiple copies of reviews were found and/or when findings conflict, we present the most recent version and the most recent conclusions.

Evidence was graded using the Grading of Recommendations Assessment, Development and Evaluation ([GRADE](#)) Working Group approach where high quality evidence such as that gained from RCTs may be downgraded to moderate or low if review and study quality is limited, if there is inconsistency in results, indirect comparisons, imprecise or sparse data and high probability of reporting bias. It may also be downgraded if risks associated with the

## Paliperidone

intervention or other matter under review are high. Conversely, low quality evidence such as that gained from observational studies may be upgraded if effect sizes are large, there is a dose dependent response or if results are reasonably consistent, precise and direct with low associated risks<sup>2</sup>. The resulting table represents an objective summary of the evidence, although the conclusions are solely the opinion of staff of NeuRA (Neuroscience Research Australia).

---

### Results

We found two reviews that met our inclusion criteria<sup>3,4</sup>.

## Paliperidone

### Compared to placebo

**Efficacy:** High quality evidence (consistent, precise, direct) suggests paliperidone is more effective at retaining patients in treatment, improving global state, and reducing psychotic relapse than placebo.

**Adverse effects:** Moderate quality evidence (imprecise) suggests paliperidone may increase the risk of tachycardia, extrapyramidal symptoms, weight gain and increased prolactin levels when compared to placebo. High quality evidence suggests paliperidone palmitate may reduce agitation or aggression more than placebo.

### Compared to second generation antipsychotic olanzapine

**Efficacy:** High quality evidence (consistent, precise, direct) suggests no difference in study retention between paliperidone and olanzapine. Moderate quality evidence (imprecise) also reports no difference in psychotic relapse rates.

**Adverse effects:** Moderate quality evidence (imprecise) suggests paliperidone may be less likely to cause weight change than olanzapine, however paliperidone may be more likely to cause extrapyramidal symptoms.

### Compared to second generation antipsychotic quetiapine

**Efficacy:** Moderate quality evidence (imprecise) suggests paliperidone improved study retention more than quetiapine.

**Adverse effects:** Moderate quality evidence (imprecise) suggests paliperidone had higher risk of hypertonia and tremor than quetiapine.

### Compared to second generation antipsychotic risperidone

**Efficacy:** High quality evidence suggests no differences for study retention or recurrence of psychotic symptoms between paliperidone palmitate and risperidone.

**Adverse effects:** High quality evidence suggests paliperidone palmitate may be associated with less use of anticholinergic medications than risperidone.

[Nussbaum AM, Stroup TS. Oral paliperidone for schizophrenia. Cochrane Database of Systematic Reviews 2008, Issue 2. Art. No.: CD006369. DOI: 10.1002/14651858.CD006369.pub2.](#)

This review included 8 RCTs (N = 2567) comparing paliperidone to placebo.

Compared to placebo, paliperidone reduced study attrition (N = 1926, 7 RCTs, RR 0.68, 95%CI 0.61 to 0.75, NNT 7 CI 6 to 10,  $I^2 = 73%$ ,  $p = 0.00099$ ) and improved global state (N = 1420, 4 RCTs, RR 0.69, 95%CI 0.63 to 0.75, NNT 5 CI 4 to 6,  $I^2 = 43%$ ,  $p = 0.16$ ). Paliperidone had a reduced chance of psychotic relapse (N = 1918, 7 RCTs, RR 0.47, 95%CI 0.34 to 0.66, NNT 17 CI 14 to 26,  $I^2 = 0%$ ,  $p = 0.52$ ).

3 RCTs (N = 1692) compared paliperidone to olanzapine.

Compared to olanzapine, no significant difference in study attrition was reported for patients on paliperidone (N = 1332, 3 RCTs, RR 1.04, 95%CI 0.89 to 1.21,  $I^2 = 0%$ ,  $p = 0.49$ ), nor in the rate of psychotic relapse (N = 1327, 3 RCTs, RR 1.07, 95%CI 0.64 to 1.76,  $I^2 = 53%$ ,  $p = 0.12$ ).

One RCT (N = not reported) compared paliperidone to risperidone.

No significant difference in rate of psychotic relapse or adverse effects was reported.

One RCT (N = 314) compared paliperidone to quetiapine.

Compared to quetiapine, paliperidone reduced study attrition (N = 314, 1 RCT, RR 0.64, 95%CI 0.44 to 0.93, NNT 9 CI 6 to 43). No significant difference was observed in the rate of psychotic relapse (N = 317, 1 RCT, RR 0.65, 95%CI 0.29 to 1.45, NNT 52).

<p><b>Risks</b></p>	<p>Compared to placebo, participants on paliperidone had increased risk of tachycardia (N = 1638, 5 RCTs, RR 1.88, 95%CI 1.28 to 2.76, NNH 21 CI 11 to 90, <math>I^2 = 0%</math>, <math>p = 0.50</math>) and elevation in serum prolactin (ng/mL) for both men (N = 568, 4 RCTs, WMD 22.12, 95%CI 21.34 to 22.89, <math>I^2 = 72%</math>, <math>p = 0.01</math>) and women (N = 335, 4 RCTs, WMD 82.50, 95%CI 78.88 to 86.13, <math>I^2 = 100%</math>, <math>p = 0.00</math>). People receiving paliperidone were more likely to experience extrapyramidal disorders (N = 1680, 6 RCTs, RR 2.27, 95%CI 1.31 to 3.95, NNH 28 CI 12 to 111, <math>I^2 = 45%</math>, <math>p = 0.10</math>) and weight gain (N = 1007, 5 RCTs, WMD 0.13, 95%CI 0.06 to 0.20, <math>I^2 = 88%</math>, <math>p = 0.00001</math>) compared with those allocated to placebo.</p> <p>Compared to olanzapine, paliperidone was associated with less weight change (N = 660, 3 RCTs, WMD -0.88, 95%CI -1.38 to -0.37, <math>I^2 = 10%</math>, <math>p = 0.33</math>). Results for various movement disorders all favoured olanzapine.</p> <p>Compared to quetiapine, participants on paliperidone were more likely to experience hypertonia (N = 317, 1 RCT, RR 3.19, 95%CI 1.31 to 7.77, NNH 13 CI 4 to 86) and tremor (N = 317, 1 RCT, RR 2.60, 95%CI 1.39 to 4.88, NNH 9 CI 4 to 34).</p>
<p><b>Consistency in results</b></p>	<p>Inconsistent for attrition, serum prolactin and weight gain vs placebo,</p>

	<p>consistent for other reported outcomes relating to placebo and olanzapine</p> <p>Not applicable for risperidone or quetiapine comparisons</p>
Precision in results	Precise for all except relapse compared to olanzapine, all quetiapine outcomes and all side effects.
Directness of results	Direct
<p><a href="#">Nussbaum AM, Stroup TS. Paliperidone palmitate for schizophrenia. Cochrane Database of Systematic Reviews 2012, Issue 6. Art. No.: CD008296. DOI: 10.1002/14651858.CD008296.pub2.</a></p>	
<p>This review included 5 RCTs (N = 2215) comparing paliperidone palmitate to placebo. Paliperidone reduced study attrition (N = 2183, 5 RCTs, RR 0.76, 95%CI 0.70 to 0.84, <math>I^2 = 45%</math>, <math>p = 0.12</math>), improved global state (N = 1696, 4 RCTs, RR 0.79, 95%CI 0.74 to 0.85, <math>I^2 = 0%</math>, <math>p = 0.64</math>), and reduced the chance of psychotic relapse (N = 2084, 5 RCTs, RR 0.58, 95%CI 0.41 to 0.81, <math>I^2 = 57%</math>, <math>p = 0.05</math>).</p> <p>2 RCTs (N = 1969) compared flexibly-dosed paliperidone palmitate (73.3 - 104.6 mg every four weeks) with flexibly-dosed risperidone long-acting injection (35.3 - 31.7 mg every two weeks).</p> <p>No differences were reported for leaving the study early for any reason (RR 1.12, 95%CI 1.00 to 1.25 <math>I^2 = 0%</math>, <math>p = 0.39</math>), or for recurrence of psychotic symptoms (RR 1.23, 95%CI 0.98 to 1.53, <math>I^2 = 0%</math>, <math>p = 0.72</math>).</p>	
Risks	<p>Compared to placebo, paliperidone palmitate was associated with fewer reports of agitation or aggression (N = 2180, 5 RCTs, RR 0.65, 95%CI 0.46 to 0.91, <math>I^2 = 42%</math>, <math>p = 0.14</math>), less use of anxiolytic medications (N = 2170, 5 RCTs, RR 0.89, 95%CI 0.83 to 0.96, <math>I^2 = 53%</math>, <math>p = 0.07</math>), but greater increase in weight (N = 2052, 5 RCTs, MD 1.34, 95%CI 0.97 to 1.70, <math>I^2 = 0%</math>, <math>p = 0.67</math>).</p> <p>Compared to risperidone long-acting injection, paliperidone palmitate was associated with less use of anticholinergic medications (N = 1587, 2 RCTs, RR 0.67, 95%CI 0.55 to 0.82, <math>I^2 = 41%</math>, <math>p = 0.19</math>).</p>
Consistency in results	Consistent
Precision in results	Precise
Directness of results	Direct

### Explanation of acronyms

CI = confidence interval,  $I^2$  = the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance), mg = milligrams, MD = mean difference, N = number of participants, NNH = number of patients needed to treat for one to show one negative effect, NNT = number of patients needed to treat for one to show a positive effect,  $p$  = statistical probability of obtaining that result ( $p < 0.05$  generally regarded as significant), RR = relative risk, vs = versus, WMD = weighted mean difference

## Paliperidone

### Explanation of technical terms

† Different effect measures are reported by different reviews.

Weighted mean difference scores refer to mean differences between treatment and comparison groups after treatment (or occasionally pre to post treatment) and in a randomised trial there is an assumption that both groups are comparable on this measure prior to treatment. Standardised mean differences are divided by the pooled standard deviation (or the standard deviation of one group when groups are homogenous) which allows results from different scales to be combined and compared. Each study's mean difference is then given a weighting depending on the size of the sample and the variability in the data. 0.2 represents a small effect, 0.5 a medium effect, and 0.8 and over represents a large effect<sup>1</sup>.

Odds ratio (OR) or relative risk (RR) refers to the probability of a reduction (< 1) or an increase (> 1) in a particular outcome in a treatment group, or a group exposed to a risk factor, relative to the comparison group. For example, a RR of 0.75 translates to a reduction in risk of an outcome of 25% relative to those not receiving the treatment or not exposed to the risk factor. Conversely, a RR of 1.25 translates to an increased risk of 25% relative to those not receiving treatment or not having been exposed to a risk factor. A RR or OR of 1.00 means there is no difference between groups. A medium effect is considered if  $RR > 2$  or  $< 0.5$  and a large effect if  $RR > 5$  or  $< 0.2^5$ . InOR stands for logarithmic OR where a lnOR of 0 shows no difference between groups. Hazard ratios measure the effect of an explanatory variable on the hazard or risk of an event.

Correlation coefficients (eg,  $r$ ) indicate the strength of association or relationship between variables. They are an indication of

prediction, but do not confirm causality due to possible and often unforeseen confounding variables. An  $r$  of 0.10 represents a weak association, 0.25 a medium association and 0.40 and over represents a strong association. Unstandardised ( $b$ ) regression coefficients indicate the average change in the dependent variable associated with a 1 unit change in the independent variable, statistically controlling for the other independent variables. Standardised regression coefficients represent the change being in units of standard deviations to allow comparison across different scales.

‡ Inconsistency refers to differing estimates of effect across studies (i.e. heterogeneity or variability in results) that is not explained by subgroup analyses and therefore reduces confidence in the effect estimate.  $I^2$  is the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance) - 0% to 40%: heterogeneity might not be important, 30% to 60%: may represent moderate heterogeneity, 50% to 90%: may represent considerable heterogeneity and over this is considerable heterogeneity.  $I^2$  can be calculated from  $Q$  (chi-square) for the test of heterogeneity with the following formula<sup>1</sup>;

$$I^2 = \left( \frac{Q - df}{Q} \right) \times 100\%$$

§ Imprecision refers to wide confidence intervals indicating a lack of confidence in the effect estimate. Based on GRADE recommendations, a result for continuous data (standardised mean differences, not weighted mean differences) is considered imprecise if the upper or lower confidence limit crosses an effect size of 0.5 in either

## Paliperidone

direction, and for binary and correlation data, an effect size of 0.25. GRADE also recommends downgrading the evidence when sample size is smaller than 300 (for binary data) and 400 (for continuous data), although for some topics, these criteria should be relaxed<sup>6</sup>.

---

|| Indirectness of comparison occurs when a comparison of intervention A versus B is not available but A was compared with C and B was compared with C, which allows indirect comparisons of the magnitude of effect of A versus B. Indirectness of population, comparator and/or outcome can also occur when the available evidence regarding a particular population, intervention, comparator, or outcome is not available and is therefore inferred from available evidence. These inferred treatment effect sizes are of lower quality than those gained from head-to-head comparisons of A and B.



### References

1. CochraneCollaboration (2008): Cochrane Handbook for Systematic Reviews of Interventions. Accessed 24/06/2011.
2. GRADEWorkingGroup (2004): Grading quality of evidence and strength of recommendations. *British Medical Journal* 328: 1490.
3. Nussbaum AM, Stroup TS (2012): Paliperidone palmitate for schizophrenia. *Cochrane Database of Systematic Reviews* 6: Art. No.: CD008296. DOI: 10.1002/14651858.CD008296.pub2.
4. Nussbaum AM, Stroup TS (2008): Oral paliperidone for schizophrenia. *Cochrane Database of Systematic Reviews*.
5. Rosenthal JA (1996): Qualitative Descriptors of Strength of Association and Effect Size. *Journal of Social Service Research* 21: 37-59.
6. GRADEpro (2008): [Computer program]. Jan Brozek, Andrew Oxman, Holger Schünemann. *Version 3.2 for Windows*